Softing AG — Regulatory Filings 2015

May 21, 2015

(CDAX, Technology)

		Value Indicators:	EUR	Share data:		Description:
Buy		DCF:	18.30	Bloomberg:	SYT GR	Software solutions (e.g. error
		FCF-Value Potential 17e:	18.70	Reuters:	SYTG	diagnosis) for industrial plants and
EUR 18.00				ISIN:	DE0005178008	automotive electronics
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2015e
		Market cap:	92.0	Freefloat	74.0 %	Beta:	1.3
Price	EUR 13.22	No. of shares (m):	7.0	Trier Asset Mgmt	26.0 %	Price / Book:	2.3 x
Upside	36.2 %	EV:	101.1			Equity Ratio:	49 %
		Freefloat MC:	68.1			Net Fin. Debt / EBITDA:	0.5 x
		Ø Trad. Vol. (30d; EUR):	136.00 th			Net Debt / EBITDA:	0.7 x

Strong order entries underpin expectation of a strong second half 2015

Stated Figures Q1/2015:								Comment on Figures:
in EUR m	Q1/15	Q1/15e	Q1/14	yoy	2015e	2014	yoy	Preliminary figures had already been made public (sales, EBIT, EPS). Revenue growth of 8% was driven by acquisitions (mainly OLDI, the
Sales	17.3	17.3	16.1	7.8%	81.0	74.5	8.7%	US subsidiary which has been consolidated since Q3 last year and is
EBITDA	2.4	2.6	2.4	0.7%	12.8	10.1	27.0%	part of Industrial Automation). Currency tailwind supported the top line.
margin	13.7%	15.0%	14.7%		15.8%	13.5%		Own work capitalised declined by more than EUR 260k having a
EBIT adjusted	1.4	1.4	1.2	22.3%	8.0	6.2	29.7%	slightly negative impact on profitability.
margin	8.4%	8.1%	7.4%		9.9%	8.3%		Industrial Automation: While Europe was weak, the US as well as Asia
EBIT	1.1	1.1	1.0	14.0%	7.7	5.9	31.2%	had a positive development.
margin	6.6%	6.4%	6.2%		9.5%	7.9%		Automotive Electronics: Last year's Q1 was extraordinarily strong due
EPS in EUR	0.11	0.11	0.10	10.0%	0.75	0.58	29.3%	to deliveries of products reaching the end of their lifecycle. New
Industrial Automation	12.9	12.9	8.4	53.1%	57.5	46.9	22.5%	generation products should be launched by the end of this year and are
EBIT Industrial Automation	1.0	0.8	0.2	305.3%	6.0	1.7	259.9%	expected to have a positive impact on revenue development thereafter.
margin	7.7%	6.2%	2.9%		10.4%	3.6%		Cost savings helped to defend profitability in this segment.
Automotive Electronics	4.4	4.4	7.6	-42.2%	23.5	27.6	-14.9%	The number of FTEs increased by 8 to 427 compared to the end of
EBIT Automotive Electronics	0.1	0.3	0.8	-80.6%	1.7	4.2	-59.2%	2014.
margin	3.3%	6.8%	9.9%		7.3%	15.3%		The EBIT adjustments are due to PPA-related amortisations
Order entries	22.0	0,0	16.4	34.1%		70.0	-	(EUR 307k vs. EUR 183k in Q1 last year).
Book-to-bill	1.3	0,0	1.0	24.4%		0.9	-	EPS: Last year's capital increase as well as a higher tax rate (32% vs. 26% a year ago) had a negative impact.

Softing's Q1 report confirmed preliminary figures. It was communicated earlier by the company that 2015 would be an H2-loaded year. The fact these statements were supported by the order entries development is regarded as positive by us. This order entries development led to a book to bill ratio of 1.3, indicating that revenues are set to increase. Furthermore, the order book nearly doubled from EUR 5.7m at the end of last year to EUR 10.4m at the end of last quarter, improving visibility for the upcoming quarters. When looking at these figures it should also be taken into account that Psiber and OLDI have short order to delivery times and, as a result, hardly contribute to the order book.

We expect the company to return to double-digit profitability levels mainly driven by higher revenue levels. Industrial Automation will show significantly stronger Q3 and Q4 revenues. The launch of the products will support growth beyond this year. Furthermore, Softing will launch new product generations in its Automotive Electronics segment. A recently signed seven-digit contract with a new customer in the area of measurement technology is also improving visibility. Against the backdrop of an improving order situation, the investment case remains intact. This theme is supported by increasing automation as well as the growing importance of electronics and networks in automotive products as structural growth drivers. In one of its recent interviews, management pointed out that by 2017 the EUR 100m revenue threshold should be reached, thus underpinning our estimates. In the medium term management targets to reach EBIT margins of up to 15%. The Buy rating as well as PT of EUR 18 are being confirmed.

in EUR m (14-17e) 10.3 % Change Sales yoy Gross profit margin EBITDA 17.8 % Margin 24.3 % Margin EBIT adj. 23.3 % Net income 27.6 %	2011 41.1 29.9 % 75.6 % 7.4 17.9 % 4.2 10.3 % 4.2	2012 49.4 20.0 % 76.3 % 8.3 16.7 % 4.9	2013 52.6 6.4 % 78.7 % 9.4 17.8 % 6.2	2014 74.5 41.8 % 68.5 % 10.1 13.5 %	2015e 81.0 8.7 % 71.0 % 12.8 15.8 %	2016e 91.0 12.3 % 71.2 % 14.8	2017e 100.0 9.9 % 71.4 % 16.5
						16.3 %	16.5 %
				5.9	7.7	9.6	11.3
		10.0 %	11.8 %	7.9 %	9.5 %	10.6 %	11.3 %
		4.9	6.2	6.2	8.0	9.9	11.6
	3.1	3.5	4.3	3.8	5.2	6.7	7.9
25.3 %	0.58	0.59	0.69	0.58	0.75	0.96	1.14
17.0 %	0.27	0.27	0.35	0.25	0.30	0.35	0.40
	6.9 %	4.6 %	3.4 %	1.6 %	2.3 %	2.6 %	3.0 %
	0.60	0.53	0.14	0.10	1.56	0.73	0.92
							0.9 x
							5.7 x
	3.5 x	4.9 x	8.7 x	20.2 x	13.1 x	10.2 x	8.3 x
	3.5 x	4.9 x	8.7 x	19.2 x	12.6 x	9.9 x	8.1 x
	6.7 x	9.9 x	15.0 x	26.3 x	17.6 x	13.8 x	11.6 x
	25.6 %	13.8 %	6.8 %	3.4 %	6.9 %	8.5 %	10.0 %
							2.1
							17.1 %
							15.7 %
	Dividend Yield FCFPS EV / Sales EV / EBITDA EV / EBIT EV / EBIT adj. FCF Yield Potential Net Debt ROCE (NOPAT) Guidance:	0.4 x 2.0 x -5.8 19.1 % 26.5 %	0.5 x 2.9 x -10.4 17.8 % 30.0 %	1.0 x 5.7 x -11.2 17.9 % 32.4 %	1.6 x 11.8 x 18.3 12.0 % 11.4 % 2015: moderate increase in sales; EBITDA/EBIT at 2014 levels	1.2 x 7.9 x 9.1 13.6 % 10.4 %	1.1 x 6.6 x 6.1 16.0 % 13.7 %

Andreas Wolf awolf@warburg-research.com +49 40 309537-140

Company Background

• Softing has the necessary expertise on information exchange between various devices, sensors, plant and software solutions in automated processes. The business activity comprises two segments.
• Industrial Automation: hardware and software solutions for the exchange of information in all kinds of production including montage lines, chemical plants, oil and gas extraction or refineries.
• Automotive Electronics: The solutions allow engineers and workshop mechanics to test automotive electronics in the development phase, production or repair, and to recognise errors through data evaluation.
• The solutions in the automotive segment are not for application within the vehicles and therefore do not pose a product re-call risk for the company.
• Softing focuses on established standards and reaches a coverage of ca. 70% of the market.

Competitive Quality

• World market leader in tools to recognise errors in production plant (so called field bus diagnostics)
• European market leader in the networking of various production plant elements as well as in business-related software (so-called OPC products).
• World market leader for components for the exchange of information in gas and oil plants. Some >50% of all devices registered worldwide that are used in these plants include components from Softing.
• Through participation in international committees that set standards for the exchange of information, a short time-to-market is achieved.
• The high complexity of the business activity of Softing is the single most important barrier to market entry for potential competitors.

DCF model

		Detailed forecast period						Transitional period						Term. Value
Figures in EUR m	2015e	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e
Sales	81.0	91.0	100.0	110.0	119.4	128.1	136.1	143.4	150.0	155.8	161.0	165.6	168.9
Sales change	8.7 %	12.3 %	9.9 %	10.0 %	8.6 %	7.3 %	6.3 %	5.3 %	4.6 %	3.9 %	3.3 %	2.9 %	2.0 %	2.0 %
EBIT	7.7	9.6	11.3	10.5	11.3	12.2	12.9	13.6	14.2	14.8	15.3	15.7	16.0
EBIT-margin	9.5 %	10.6 %	11.3 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %	9.5 %
Tax rate (EBT)	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %
NOPAT	5.4	6.7	7.9	7.3	7.9	8.5	9.1	9.5	10.0	10.4	10.7	11.0	11.2
Depreciation	5.1	5.2	5.2	7.2	7.8	8.3	8.8	9.3	9.7	10.1	10.5	10.8	11.0
in % of Sales	6.3 %	5.7 %	5.2 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %
Changes in provisions	0.0	0.0	0.0	0.8	0.1	0.1	0.0	0.0	0.0	0.0	-0.1	-0.1	-0.1
Change in Liquidity from
- Working Capital	-5.4	2.0	1.8	2.1	1.6	1.5	1.4	1.3	1.1	1.0	0.9	0.8	0.6
- Capex	4.8	4.8	4.9	7.4	8.0	8.6	9.1	9.6	10.0	10.4	10.8	11.1	11.3
Capex in % of Sales	5.9 %	5.3 %	4.9 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %	6.7 %
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Free Cash Flow (WACC Model)	11.1	5.1	6.4	5.9	6.1	6.8	7.4	8.0	8.5	9.0	9.4	9.8	10.2	11
PV of FCF	11.1	4.8	5.6	4.8	4.7	4.8	4.9	4.9	4.9	4.8	4.7	4.6	4.5	90
share of PVs		13.53 %						29.95 %						56.52 %
Model parameter								Valuation (m)
Derivation of WACC:			Derivation of Beta:					Present values 2027e			69
								Terminal Value			90
Debt ratio	20.00 %		Financial Strength			1.25		Financial liabilities			38
Cost of debt (after tax)	2.2 %		Liquidity (share)			1.25		Pension liabilities			2
Market return	7.00 %		Cyclicality			1.25		Hybrid capital			0
Risk free rate	1.50 %		Transparency			1.25		Minority interest			0
			Others			1.25		Market val. of investments			0
							Liquidity				9	No. of shares (m)		7.0
WACC	7.15 %		Beta			1.25	Equity Value			127		Value per share (EUR)		18.28

Sensitivity Value per Share (EUR)

	Terminal Growth								Delta EBIT-margin
Beta WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta WACC	-1.5 pp	-1.0 pp		-0.5 pp +0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.48 8.1 %	13.52	13.84	14.19	14.57	14.98	15.42	15.91	1.48 8.1 %	11.34	12.41	13.49	14.57	15.65	16.72	17.80
1.36 7.6 %	14.95	15.35	15.79	16.26	16.77	17.34	17.96	1.36 7.6 %	12.74	13.91	15.08	16.26	17.43	18.61	19.78
1.31 7.4 %	15.76	16.21	16.69	17.22	17.80	18.44	19.15	1.31 7.4 %	13.53	14.76	15.99	17.22	18.45	19.68	20.91
1.25 7.1 %	16.64	17.14	17.68	18.28	18.94	19.67	20.48	1.25 7.1 %	14.41	15.70	16.99	18.28	19.57	20.86	22.15
1.19 6.9 %	17.60	18.16	18.77	19.45	20.20	21.03	21.97	1.19 6.9 %	15.38	16.73	18.09	19.45	20.81	22.17	23.52
1.14 6.6 %	18.65	19.28	19.98	20.75	21.61	22.57	23.65	1.14 6.6 %	16.45	17.88	19.31	20.75	22.18	23.61	25.04
1.02 6.1 %	21.07	21.89	22.80	23.82	24.96	26.27	27.77	1.02 6.1 %	18.99	20.60	22.21	23.82	25.42	27.03	28.64

The cyclical components of the business activity and the low liquidity of the share raise the capital costs.

Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Net Income before minorities	3.1	3.5	4.3	3.8	5.2	6.7	7.9
+ Depreciation + Amortisation	3.1	3.3	3.2	4.2	5.1	5.2	5.2
- Net Interest Income	0.0	0.0	-0.1	-0.3	-0.3	-0.1	0.0
- Maintenance Capex	2.3	3.5	3.9	4.2	3.6	3.6	3.7
+ Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Free Cash Flow Potential	3.9	3.3	3.7	4.1	7.0	8.4	9.4
Free Cash Flow Yield Potential	25.6 %	13.8 %	6.8 %	3.4 %	6.9 %	8.5 %	10.0 %
WACC	7.15 %	7.15 %	7.15 %	7.15 %	7.15 %	7.15 %	7.15 %
= Enterprise Value (EV)	15.0	24.2	53.7	119.1	101.1	98.1	94.1
= Fair Enterprise Value	53.9	46.9	51.1	56.8	97.9	117.2	132.0
- Net Debt (Cash)	16.1	16.1	16.1	16.1	6.9	4.0	0.0
- Pension Liabilities	2.2	2.2	2.2	2.2	2.2	2.2	2.2
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
- Market value of minorities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	35.7	28.6	32.9	38.5	88.7	111.1	129.9
No. of shares (total) (m)	7.0	7.0	7.0	7.0	7.0	7.0	7.0
= Fair value per share (EUR)	5.12	4.11	4.72	5.54	12.75	15.96	18.66
premium (-) / discount (+) in %					-3.5 %	20.8 %	41.1 %
Sensitivity Fair value per Share (EUR)
10.15 %	2.83	2.12	2.55	3.12	8.60	10.99	13.05
9.15 %	3.43	2.64	3.12	3.75	9.68	12.28	14.51
8.15 %	4.17	3.28	3.82	4.53	11.03	13.90	16.33
WACC 7.15 %	5.12	4.11	4.72	5.54	12.75	15.96	18.66
6.15 %	6.38	5.21	5.92	6.86	15.04	18.70	21.74
5.15 %	8.13	6.73	7.58	8.71	18.22	22.51	26.03
4.15 %	10.73	8.98	10.04	11.44	22.92	28.15	32.38

Capitalised own work is a significant element of the capex.

The earnings quality has clearly improved over the last years.

Increasing share of software revenues should have a positive effect on the FCF Value.

Valuation

	2011	2012	2013	2014	2015e	2016e	2017e
Price / Book	1.2 x	1.6 x	2.5 x	2.7 x	2.3 x	2.1 x	1.9 x
Book value per share ex intangibles	1.96	2.43	2.62	-0.60	-0.03	0.66	1.50
EV / Sales	0.4 x	0.5 x	1.0 x	1.6 x	1.2 x	1.1 x	0.9 x
EV / EBITDA	2.0 x	2.9 x	5.7 x	11.8 x	7.9 x	6.6 x	5.7 x
EV / EBIT	3.5 x	4.9 x	8.7 x	20.2 x	13.1 x	10.2 x	8.3 x
EV / EBIT adj.*	3.5 x	4.9 x	8.7 x	19.2 x	12.6 x	9.9 x	8.1 x
P / FCF	6.5 x	11.0 x	72.4 x	149.6 x	8.4 x	18.1 x	14.4 x
P / E	6.7 x	9.9 x	15.0 x	26.3 x	17.6 x	13.8 x	11.6 x
P / E adj.*	6.7 x	9.9 x	15.0 x	26.3 x	17.6 x	13.8 x	11.6 x
Dividend Yield	6.9 %	4.6 %	3.4 %	1.6 %	2.3 %	2.6 %	3.0 %
Free Cash Flow Yield Potential	25.6 %	13.8 %	6.8 %	3.4 %	6.9 %	8.5 %	10.0 %
*Adjustments made for: -

Company Specific Items

	2011	2012	2013	2014	2015e	2016e	2017e
order entries	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
book-to-bill	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
order book	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.

Consolidated profit & loss

In EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Sales	41.1	49.4	52.6	74.5	81.0	91.0	100.0
Change Sales yoy	29.9 %	20.0 %	6.4 %	41.8 %	8.7 %	12.3 %	9.9 %
Increase / decrease in inventory	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	2.0	3.2	4.0	3.9	3.2	2.9	2.9
Total Sales	43.2	52.6	56.5	78.5	84.2	93.9	102.9
Material Expenses	12.1	14.9	15.2	27.4	26.7	29.1	31.5
Gross profit	31.1	37.7	41.3	51.1	57.5	64.8	71.4
Gross profit margin	75.6 %	76.3 %	78.7 %	68.5 %	71.0 %	71.2 %	71.4 %
Personnel expenses	19.4	23.6	25.8	32.1	35.0	39.0	43.2
Other operating income	1.7	0.9	0.7	0.8	0.8	0.8	0.8
Other operating expenses	6.1	6.8	6.8	9.7	10.4	11.7	12.5
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	7.4	8.3	9.4	10.1	12.8	14.8	16.5
Margin	17.9 %	16.7 %	17.8 %	13.5 %	15.8 %	16.3 %	16.5 %
Depreciation of fixed assets	0.3	0.5	0.5	0.6	1.1	1.2	1.2
EBITA	7.1	7.8	8.9	9.5	11.7	13.6	15.3
Amortisation of intangible assets	2.8	2.9	2.7	3.7	4.0	4.0	4.0
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	4.2	4.9	6.2	5.9	7.7	9.6	11.3
Margin	10.3 %	10.0 %	11.8 %	7.9 %	9.5 %	10.6 %	11.3 %
EBIT adj.	4.2	4.9	6.2	6.2	8.0	9.9	11.6
Interest income	0.3	0.3	0.2	0.2	0.0	0.1	0.1
Interest expenses	0.3	0.2	0.2	0.4	0.3	0.2	0.1
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	4.2	4.9	6.2	5.6	7.4	9.5	11.3
Margin	10.3 %	10.0 %	11.7 %	7.5 %	9.2 %	10.5 %	11.3 %
Total taxes	1.2	1.4	1.9	1.8	2.2	2.9	3.4
Net income from continuing operations	3.1	3.5	4.3	3.8	5.2	6.7	7.9
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	3.1	3.5	4.3	3.8	5.2	6.7	7.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	3.1	3.5	4.3	3.8	5.2	6.7	7.9
Margin	7.5 %	7.1 %	8.2 %	5.1 %	6.4 %	7.3 %	7.9 %
Number of shares, average	5.3	5.9	6.3	6.6	7.0	7.0	7.0
EPS	0.58	0.59	0.69	0.58	0.75	0.96	1.14
EPS adj.	0.58	0.59	0.69	0.58	0.75	0.96	1.14
*Adjustments made for:

Guidance: 2015: moderate increase in sales; EBITDA/EBIT at 2014 levels

Financial Ratios

	2011	2012	2013	2014	2015e	2016e	2017e
Total Operating Costs / Sales	87.0 %	89.7 %	89.7 %	91.7 %	88.1 %	86.9 %	86.4 %
Operating Leverage	5.9 x	0.8 x	4.1 x	-0.1 x	3.6 x	2.0 x	1.7 x
EBITDA / Interest expenses	29.1 x	33.7 x	45.7 x	23.3 x	42.7 x	74.2 x	165.0 x
Tax rate (EBT)	28.1 %	29.0 %	30.2 %	32.3 %	30.0 %	30.0 %	30.0 %
Dividend Payout Ratio	47.1 %	45.8 %	51.1 %	43.4 %	40.2 %	36.5 %	35.2 %
Sales per Employee	159,488	166,851	155,936	181,345	180,000	189,583	208,333

Operating Performance

Sales, EBITDA in EUR m

Performance per Share

Consolidated balance sheet

In EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Assets
Goodwill and other intangible assets	6.7	7.8	9.7	41.0	39.8	39.1	38.5
thereof other intangible assets	0.7	0.6	0.5	22.2	21.6	21.0	20.4
thereof Goodwill	2.4	2.4	2.4	14.5	14.5	14.5	14.5
Property, plant and equipment	1.1	1.4	1.4	1.9	1.9	1.8	1.7
Financial assets	0.9	0.7	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	8.7	9.9	11.1	42.9	41.7	40.9	40.2
Inventories	3.6	3.3	4.7	8.7	4.5	5.4	6.3
Accounts receivable	8.3	9.8	10.0	14.2	13.3	15.0	16.4
Liquid assets	8.5	12.6	12.9	8.8	18.9	18.9	17.9
Other short-term assets	1.7	2.3	1.5	2.4	2.4	2.4	2.4
Current assets	22.2	28.0	29.1	34.1	39.1	41.7	43.0
Total Assets	31.0	37.9	40.2	77.0	80.8	82.6	83.2
Liabilities and shareholders' equity
Subscribed capital	5.6	6.4	6.4	7.0	7.0	7.0	7.0
Capital reserve	1.7	4.4	4.4	12.3	12.3	12.3	12.3
Retained earnings	10.6	12.1	15.6	18.0	23.2	29.9	37.8
Other equity components	-0.8	-0.8	-0.3	-0.2	-2.9	-5.4	-8.1
Shareholder's equity	17.2	22.2	26.2	37.0	39.6	43.8	48.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	17.2	22.2	26.1	37.0	39.5	43.7	48.9
Provisions	1.7	3.0	2.3	3.9	3.9	3.9	3.9
thereof provisions for pensions and similar obligations	1.0	1.8	1.5	2.2	2.2	2.2	2.2
Financial liabilites (total)	1.8	0.5	0.2	24.8	25.9	22.9	17.9
thereof short-term financial liabilities	0.0	0.0	0.0	7.0	7.0	7.0	7.0
Accounts payable	2.9	3.0	2.5	4.2	4.4	5.0	5.5
Other liabilities	7.4	9.3	9.0	7.1	7.1	7.1	7.1
Liabilities	13.8	15.7	14.1	40.0	41.2	38.8	34.3
Total liabilities and shareholders' equity	31.0	37.9	40.2	77.0	80.8	82.6	83.2

Financial Ratios 2011 2012 2013 2014 2015e 2016e 2017e Efficiency of Capital Employment Operating Assets Turnover 4.0 x 4.2 x 3.9 x 3.6 x 5.3 x 5.3 x 5.3 x Capital Employed Turnover 3.6 x 4.2 x 3.5 x 1.3 x 1.7 x 1.8 x 2.0 x ROA 35.1 % 35.6 % 38.9 % 8.9 % 12.5 % 16.3 % 19.7 % Return on Capital ROCE (NOPAT) 26.5 % 30.0 % 32.4 % 11.4 % 10.4 % 13.7 % 15.7 % ROE 19.1 % 17.8 % 17.9 % 12.0 % 13.6 % 16.0 % 17.1 % Adj. ROE 19.1 % 17.8 % 17.9 % 12.0 % 13.6 % 16.0 % 17.1 % Balance sheet quality Net Debt -5.8 -10.4 -11.2 18.3 9.1 6.1 2.1 Net Financial Debt -6.8 -12.1 -12.7 16.1 6.9 4.0 0.0 Net Gearing -33.5 % -46.7 % -42.9 % 49.4 % 23.0 % 14.0 % 4.4 % Net Fin. Debt / EBITDA n.a. n.a. n.a. 159.4 % 54.2 % 26.7 % n.a. Book Value / Share 3.2 3.7 4.2 5.6 5.7 6.3 7.0 Book value per share ex intangibles 2.0 2.4 2.6 -0.6 0.0 0.7 1.5

CO M M E N T Published 21.05.2015 7

Consolidated cash flow statement

In EUR m	2011	2012	2013	2014	2015e	2016e	2017e
Net income	3.1	3.5	4.3	3.8	5.2	6.7	7.9
Depreciation of fixed assets	0.3	0.5	0.5	0.6	1.1	1.2	1.2
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	2.8	2.9	2.7	3.7	4.0	4.0	4.0
Increase/decrease in long-term provisions	0.2	0.0	-0.1	0.0	0.0	0.0	0.0
Other non-cash income and expenses	1.1	1.4	0.7	0.5	0.0	0.0	0.0
Cash Flow	7.5	8.2	8.0	8.5	10.3	11.9	13.1
Increase / decrease in inventory	-0.8	0.3	-1.3	-1.6	4.2	-0.9	-0.9
Increase / decrease in accounts receivable	-0.2	-1.8	-0.2	-0.7	0.9	-1.7	-1.4
Increase / decrease in accounts payable	-0.2	1.1	-0.4	-0.9	0.2	0.6	0.5
Increase / decrease in other working capital positions	0.0	0.0	-0.1	0.9	0.0	0.0	0.0
Increase / decrease in working capital (total)	-1.2	-0.5	-2.0	-2.2	5.4	-2.0	-1.8
Net cash provided by operating activities	6.3	7.8	6.0	6.3	15.7	9.9	11.3
Investments in intangible assets	-2.4	-3.9	-4.6	-4.3	-3.7	-3.7	-3.8
Investments in property, plant and equipment	-0.7	-0.7	-0.5	-1.4	-1.1	-1.1	-1.1
Payments for acquisitions	0.0	0.0	0.0	-21.9	0.0	0.0	0.0
Financial investments	0.6	0.2	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.2	0.8	0.0	0.0	0.0
Net cash provided by investing activities	-2.5	-4.4	-4.9	-26.7	-4.8	-4.8	-4.9
Change in financial liabilities	0.0	-1.2	0.0	10.6	1.0	-3.0	-5.0
Dividends paid	-0.6	-1.4	-1.7	-1.3	-1.7	-2.1	-2.4
Purchase of own shares	0.0	0.0	1.3	0.5	0.0	0.0	0.0
Capital measures	0.0	3.5	0.0	7.5	0.0	0.0	0.0
Other	-0.2	0.0	-0.1	-0.3	0.0	0.0	0.0
Net cash provided by financing activities	-0.8	0.9	-0.5	17.0	-0.7	-5.1	-7.4
Change in liquid funds	3.0	4.2	0.6	-3.4	10.2	0.0	-1.0
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.1	0.0	0.0	0.0
Cash and cash equivalent at end of period	7.3	11.5	12.1	8.8	18.9	18.9	17.9

Financial Ratios

	2011	2012	2013	2014	2015e	2016e	2017e
Cash Flow
FCF	3.2	3.1	0.9	0.7	10.9	5.1	6.4
Free Cash Flow / Sales	7.8 %	6.4 %	1.7 %	0.9 %	13.4 %	5.6 %	6.4 %
Free Cash Flow Potential	3.9	3.3	3.7	4.1	7.0	8.4	9.4
Free Cash Flow / Net Profit	104.4 %	89.3 %	20.8 %	17.7 %	209.6 %	76.0 %	81.0 %
Interest Received / Avg. Cash	3.5 %	2.4 %	1.2 %	1.5 %	0.0 %	0.5 %	0.5 %
Interest Paid / Avg. Debt	14.8 %	21.9 %	56.9 %	3.5 %	1.2 %	0.8 %	0.5 %
Management of Funds
Investment ratio	7.5 %	9.4 %	9.8 %	7.6 %	5.9 %	5.3 %	4.9 %
Maint. Capex / Sales	5.7 %	7.1 %	7.3 %	5.7 %	4.4 %	4.0 %	3.7 %
Capex / Dep	99.2 %	139.1 %	162.5 %	133.8 %	94.1 %	92.3 %	94.2 %
Avg. Working Capital / Sales	19.6 %	19.6 %	21.3 %	20.8 %	19.9 %	15.8 %	16.3 %
Trade Debtors / Trade Creditors	290.4 %	333.8 %	396.0 %	339.9 %	302.3 %	300.0 %	298.2 %
Inventory Turnover	3.3 x	4.5 x	3.3 x	3.1 x	5.9 x	5.4 x	5.0 x
Receivables collection period (days)	74	73	70	70	60	60	60
Payables payment period (days)	86	72	61	56	60	63	64
Cash conversion cycle (Days)	46	26	73	83	11	16	21

CAPEX and Cash Flow in EUR m

Working Capital

CO M M E N T Published 21.05.2015 8

LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.

2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.

3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.

4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordiance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

-1- The company preparing the analysis or any of its affiliated companies hold over 5% of shares in the analysed company's equity capital. -2- Within the last twelve months, the company preparing the analysis or any of its affiliated companies have participated in the management of a consortium for the public offering of financial securities, which are (or the issuer of which) is the subject of the analysis. -3- The company preparing the analysis or any of its affiliated companies manage the securities of the analysed company on the grounds of an existing contract. -4- On the grounds of an existing contract, the company preparing the analysis or any of its affiliated companies, have managed investment banking services for the analysed company within the last twelve months, out of which a service or the promise of a has service emerged. -5- The company preparing the analysis and the analysed company came to an agreement regarding the preparation of the financial analysis. -6- The company preparing the analysis or any of its affiliated companies regularly trade in shares or derivatives of the analysed company. -7- The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Softing	4, 5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005178008.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months. The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months. The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:
-S-	Sell:
"-"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – RESEARCH UNIVERSE BY RATING

Rating	Number of stocks	% of Universe
Buy	99	54
Hold	73	40
Sell	7	4
Rating suspended	3	2
Total	182	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING …

… Looking only at companies for which a disclosure according to § 34b of the Germany Securities Trading Act and the FinAnV has to be made.

Rating	Number of stocks	% of Universe
Buy	82	61
Hold	47	35
Sell	4	3
Rating suspended	2	1
Total	135	100

PRICE AND RATING HISTORY SOFTING AS OF 21.05.2015

The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.

EQUITIES
----------

Roland Rapelius +49 40 3282-2673

RESEARCH

SALES TRADING

INSTITUTIONAL EQUITY SALES

Head of Equities rrapelius@mmwarburg.com Retail, Consumer Goods tkleibauer@warburg-research.com Software, IT awolf@warburg-research.com Eggert Kuls +49 40 309537-256 Engineering ekuls@warburg-research.com Frank Laser +49 40 309537-235 Construction, Industrials flaser@warburg-research.com Andreas Pläsier +49 40 309537-246 Banks, Financial Services aplaesier@warburg-research.com

Henner Rüschmeier +49 40 309537-270 Malte Räther +49 40 309537-185 Head of Research hrueschmeier@warburg-research.com Technology, Telco, Internet mraether@warburg-research.com Lucas Boventer +49 40 309537-290 Jochen Reichert +49 40 309537-130 Others lboventer@warburg-research.com Telco, Internet, Media jreichert@warburg-research.com Christian Cohrs +49 40 309537-175 Arash Roshan Zamir +49 40 309537-155 Engineering, Logistics ccohrs@warburg-research.com Engineering, Logistics aroshanzamir@warburg-research.com Felix Ellmann +49 40 309537-120 Malte Schaumann +49 40 309537-170 Software, IT fellmann@warburg-research.com Technology mschaumann@warburg-research.com Jörg Philipp Frey +49 40 309537-258 Oliver Schwarz +49 40 309537-250 Retail, Consumer Goods jfrey@warburg-research.com Chemicals, Agriculture oschwarz@warburg-research.com Harald Hof +49 40 309537-125 Marc-René Tonn +49 40 309537-259 Medtech hhof@warburg-research.com Automobiles, Car Suppliers mtonn@warburg-research.com Ulrich Huwald +49 40 309537-255 Björn Voss +49 40 309537-254 Health Care, Pharma uhuwald@warburg-research.com Steel, Car Suppliers bvoss@warburg-research.com Thilo Kleibauer +49 40 309537-257 Andreas Wolf +49 40 309537-140

Holger Nass +49 40 3282-2669 Ömer Güven +49 40 3282-2633 Head of Equity Sales, USA hnass@mmwarburg.com USA, Germany ogueven@mmwarburg.com Klaus Schilling +49 40 3282-2664 Michael Kriszun +49 40 3282-2695 Dep. Head of Equity Sales, GER kschilling@mmwarburg.com United Kingdom mkriszun@mmwarburg.com Christian Alisch +49 40 3282-2667 Marc Niemann +49 40 3282-2660 Scandinavia, Spain calisch@mmwarburg.com Germany mniemann@mmwarburg.com Tim Beckmann +49 40 3282-2665 Sanjay Oberoi +49 69 5050-7410 United Kingdom tbeckmann@mmwarburg.com United Kingdom soberoi@mmwarburg.com Matthias Fritsch +49 40 3282-2696 Philipp Stumpfegger +49 40 3282-2635 United Kingdom mfritsch@mmwarburg.com Australia, United Kingdom pstumpfegger@mmwarburg.com Marie-Therese Grübner +49 40 3282-2630 Juliane Willenbruch +49 40 3282-2694

France, Switzerland mgruebner@mmwarburg.com Roadshow/Marketing jwillenbruch@mmwarburg.com

Oliver Merckel +49 40 3282-2634 Bastian Quast +49 40 3282-2701 Head of Sales Trading omerckel@mmwarburg.com Sales Trading bquast@mmwarburg.com Thekla Struve +49 40 3282-2668 Jörg Treptow +49 40 3262-2658 Dep. Head of Sales Trading tstruve@mmwarburg.com Sales Trading jtreptow@mmwarburg.com Gudrun Bolsen +49 40 3282-2679 Jan Walter +49 40 3262-2662 Sales Trading gbolsen@mmwarburg.com Sales Trading jwalter@mmwarburg.com

Michael Ilgenstein +49 40 3282-2700 Sales Trading milgenstein@mmwarburg.com MACRO RESEARCH Carsten Klude +49 40 3282-2572 Dr. Christian Jasperneite +49 40 3282-2439 Macro Research cklude@mmwarburg.com Investment Strategy cjasperneite@mmwarburg.com Matthias Thiel +49 40 3282-2401 Macro Research mthiel@mmwarburg.com Our research can be found under: Warburg Research research.mmwarburg.com/en/index.html Thomson www.thomson.com Bloomberg MMWA GO Reuters www.knowledge.reuters.com

For access please contact: Andrea Schaper +49 40 3282-2632 Kerstin Muthig +49 40 3282-2703 Sales Assistance aschaper@mmwarburg.com Sales Assistance kmuthig@mmwarburg.com

FactSet www.factset.com Capital IQ www.capitaliq.com